About this Research Topic
Contributions will provide insights into conceptualizing from experimental models (mouse and pig) to spontaneous disease (dog and human) clients to avoid gaps and increase therapeutic value. The scope of topics includes the development of large animal clinical trial networks, incorporating FDA requirements into creating experimental and spontaneous validated/qualified alternative clinical models. The ability to produce experimental animals that exhibit clinically relevant comorbidities through either experimental approaches or crossing animals with fixed phenotypes will also be covered. Relevant targeted comorbidities include alcohol-induced cirrhosis, nonalcoholic steatohepatitis (NASH), diabetes, obesity, and cardiovascular disease. In addition, both experimental (porcine) and spontaneous (canine) large animal cancer models are being recognized by the National Cancer Institute as valuable tools for testing of drugs and devices in co-clinical trials; hence reducing the accrual time for launching a human clinical trial. However, there are also clinical gaps in expertise that need to be addressed in order to fully realize the power of co-clinical trials. This Research Topic will also address training needs with regards to comparative pathology and the development of imaging standards to support relevant interpretation of findings and expedite the launch of human clinical trials.
Keywords: Translational, transitional, cancer phenotypes, comparative pathology, co-clinical trials
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.